- Home
- SCLX vs STEC Comparison
SCLX vs STEC Comparison
Compare SCLX & STEC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCLX
- STEC
- Stock Information
- Founded
- SCLX 2011
- STEC 2006
- Country
- SCLX United States
- STEC China
- Employees
- SCLX N/A
- STEC N/A
- Industry
- SCLX Biotechnology: Pharmaceutical Preparations
- STEC
- Sector
- SCLX Health Care
- STEC
- Exchange
- SCLX Nasdaq
- STEC NYSE
- Market Cap
- SCLX 33.9M
- STEC 29.7M
- IPO Year
- SCLX N/A
- STEC 2021
- Fundamental
- Price
- SCLX $5.70
- STEC $0.85
- Analyst Decision
- SCLX Strong Buy
- STEC
- Analyst Count
- SCLX 3
- STEC 0
- Target Price
- SCLX $367.50
- STEC N/A
- AVG Volume (30 Days)
- SCLX 125.0K
- STEC 13.5K
- Earning Date
- SCLX 08-12-2025
- STEC 07-01-2025
- Dividend Yield
- SCLX N/A
- STEC N/A
- EPS Growth
- SCLX N/A
- STEC N/A
- EPS
- SCLX N/A
- STEC N/A
- Revenue
- SCLX $50,710,000.00
- STEC $10,672,000.00
- Revenue This Year
- SCLX $107.00
- STEC $9,392.20
- Revenue Next Year
- SCLX $82.52
- STEC N/A
- P/E Ratio
- SCLX N/A
- STEC N/A
- Revenue Growth
- SCLX 7.79
- STEC 50.79
- 52 Week Low
- SCLX $3.60
- STEC $0.20
- 52 Week High
- SCLX $78.05
- STEC $3.25
- Technical
- Relative Strength Index (RSI)
- SCLX 49.86
- STEC 32.31
- Support Level
- SCLX $4.53
- STEC $0.80
- Resistance Level
- SCLX $5.60
- STEC $1.00
- Average True Range (ATR)
- SCLX 0.41
- STEC 0.10
- MACD
- SCLX 0.01
- STEC -0.02
- Stochastic Oscillator
- SCLX 31.96
- STEC 0.00
About SCLX Scilex Holding Company
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.
About STEC SANTECH HOLDINGS LIMITED
Santech Holdings Ltd is a customer based technology company. The company is engaged in exploring new opportunities in technology that includes new retail, social e-commerce, metaverse and others.